MorphoSys’s worldwide partnering track record spans a wide range of agreements, from collaborations with academia and innovative biopharmaceutical start-ups to drug discovery alliances with several of the largest pharmaceutical companies like Novartis, Roche, Johnson & Johnson/Janssen, Pfizer, Bayer and Boehringer Ingelheim. For the further development and commercialization of our proprietary clinical-stage programs we have been able to attract GlaxoSmithKline, amongst others. These productive partnerships have resulted in one of the largest therapeutic antibody pipelines to date.
MorphoSys is dedicated to becoming a fully integrated biopharmaceutical company including late-stage clinical development and marketing/co-promotion of its own drugs. With our goal of engineering the medicines of tomorrow in mind, we are always interested in new collaborations with innovative, science-driven organizations and academic institutions.